Vaccines — Editors

Journal Contact

Vaccines Editorial Office
MDPI AG, St. Alban-Anlage 66, 4052 Basel, Switzerland
Tel. +41 61 683 77 34; Fax: +41 61 302 89 18
Ms. Qingjuan Yang

Assistant Editor
MDPI Tongzhou Office, Room 2207, Jincheng Center, No. 21 Cuijingbeili, Tongzhou District, Beijing 101101, China
Tel. +86 10 8152 1170; Fax: +86 10 5901 1089


Prof. Dr. Diane M. Harper

Professor of Family and Geriatric Medicine, Obstetrics and Gynecology, Bioengineering, Epidemiology and Population Health, Health Promotions and Behavioral Sciences, University of Louisville School of Medicine, 501 East Broadway, Louisville, KY 40202, USA
Interests: cervical cancer prevention; HPV vaccine, HPV prevention; HPV cure; CIN detection; CIN cure; quality of life; shared decision making; communications

Editorial Board

Prof. Dr. Pedro L. Alonso

Barcelona Center for International Health Research(CRESIB), University of Barcelona, Villarroel 170, 08036 Barcelona, Spain
Interests: public health; host-pathogen interaction; Malaria; viral and bacterial infections; HIV/AIDS and STI’s
Dr. Rolf Billeskov

Department of Infectious Disease Immunology, Division of Vaccine, Statens Serum Institut, Artillerivej 5, DK-2300 Copenhagen S, Denmark Institute of International Health, Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
Interests: immunology; T cells; tuberculosis; polyfunctionality of T cells; T cell avidity; vaccines
Dr. Joseph E. Blaney, Jr.

Emerging Viral Pathogens Section, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 8200 Research Plaza, Room 1A-124, Fort Detrick, MD 21702, USA
Interests: Viral vaccines, pathogenesis of emerging viruses, biodefense, animal model development
Prof. Dr. Thierry Boon

de Duve Institute, Université Catholique de Louvain and Ludwig Institute for Cancer Research, Brussels Branch Avenue Hippocrate, 74 B1.74.03, B-1200 Brussels, Belgium
Interests: The work of our group is aimed at understanding why some metastatic melanoma patients show tumor regression following vaccination whereas most patients do not. Recent results suggest that a local immunosuppressive environment at the tumor sites may be the main barrier to the efficacy of immunotherapy.
Prof. Dr. Olga Borges

Center for Neuroscience and Cell Biology & Faculty of Pharmacy, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal
Website: |
Interests: focussed on the development of polymeric carriers as adjuvants for mucosal vaccination (protein and DNA) and examination of the interactions of delivery systems with biological targets in vitro and in vivo
Contribution: Special Issue: Nanoparticles to Co-Deliver Immunopotentiators and Antigens
Dr. Sandra S. Chaves

Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, Georgia 30333, USA
Interests: infectious disease epidemiology; influenza; duration of vaccine-induced immunity; influenza treatment; influenza prevention
Dr. Genoveffa Franchini

Animal Models & Retroviral Vaccine Section, Vaccine Branch, National Cancer Institute, National Institute of Health, 9000 Rockville Pike, Bethesda MD, 20892, USA
Interests: immunology, virology, vaccines; HTLV; SIV; animal models; vaccine development
Prof. Dr. Eli Gilboa

Department of Microbiology and Immunology, Dodson Interdisciplinary Immunotherapy Institute and the Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, 1550 NW 10th Avenue, Room 211, Papanicolaou Cancer Research Building, Miami, FL 33136, USA
Interests: My laboratory is using murine tumor models to develop a multi-pronged strategy to elicit clinically-useful antitumor immune responses in cancer patients. The current main strategy is to develop immune modulatory agents composed of short oligonucleotides (siRNAs, aptamers, antagomirs) that are targeted to the tumor or the tumor-activated immune system by conjugation to oligonucleotide aptamer ligands
Prof. Dr. Marc P. Girard

University Paris 7, French National Academy of Medicine, 49 rue D'Aubigny, FR 69003 Lyon, France
Interests: viral vaccine research and development: HIV vaccines, influenza vaccines, lentiviruses; vaccinology in general; and anti-viral immune responses: neutralizing antibodies, ADCC and ADCVI, CD8+ T cell responses, innate immunity responses, mucosal immunity
Dr. Elena A. Govorkova

Department of Infectious Diseases, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105-3678, USA
Interests: antiviral drugs for the control of influenza infection, including H5N1 influenza viruses: assessment of antiviral drug efficacy in vitro and in vivo; evaluation of viral fitness; combination chemotherapy; influenza vaccines: immunogenicity and protective efficacy
Dr. Guido Grandi

Novartis Vaccines and Diagnostics, Research Center, Via Fiorentina 1, 53100 Siena, Italy
Interests: bacterial infectious diseases; group A streptococcus; group B streptococcus; S. aureus; Chlamydia; vaccine development; proteomics; genomics; high throughput technologies
Prof. Dr. Chinnaswamy Jagannath

Department of Pathology and Laboratory Medicine, University of Texas Health Sciences Center, 6400 Fannin Street, MSB 2.200, Houston, TX 77030, USA
Interests: vaccines for tuberculosis; TLR signaling and adjuvants; Th1 immunity and T cells; Dendritic cells and macrophages-pathogen survival
Contribution: Special Issue: Tuberculosis Vaccines
Dr. Aisha O. Jumaan

TEPHNET-Centers for Disease Control and Prevention, 3216 74th Place SE. Mercer Island, WA 98040, USA
Interests: vaccines; vaccine preventable diseases; vaccine effectiveness; infectious diseases; breast and cervical cancers; maternal and child health
Prof. Dr. Matti Osmo Antero Lehtinen

School of Health Sciences, University of Tampere, Sorinkatu 1, 33014 Tampere, Finland
Interests: cancer; tumor viruses; immune response; infectious disease epidemiology; sexually transmitted infections; translational medicine
Prof. Dr. Margaret A. Liu

1 ProTherImmune, 3656 Happy Valley Road Lafayette, CA 94549, USA
2 Karolinska Institute, Stockholm SE-17177, Sweden
3. Adjunct Professor, Department of Microbiology and Immunology, University of California, San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143 USA
Interests: vaccine technologies; DNA vaccines; cellular immune responses; HIV Vvccines; global health
Contribution: Special Issue: DNA Vaccines
Prof. Dr. Abu Salim Mustafa

Department of Microbiology, Faculty of Medicine, Kuwait University PO Box 24923, Safat 13110, Kuwait
Interests: Tuberculosis; vaccines; immunodiagnosis; immuno-pathogenesis
Contribution: Special Issue: Tuberculosis Vaccines
Prof. Dr. Toshi Nagata

Department of Health Science, Hamamatsu University School of Medicine, 1-20-1 Handa-yama, Higashi-ku, Hamamatsu 431-3192, Japan
Interests: intracellular bacteria; T cell responses; DNA vaccines; HLA; antigen presentation; tuberculosis
Prof. Dr. Sven-Eric Olsson

Karolinska Institute at Danderyd Hospital, SE-182 88 Stockholm, Sweden
Interests: HPV vaccines; dysplasias and treatment options; immunological memory; cervical cancer screeningHPV vaccines; dysplasias and treatment options; immunological memory; cervical cancer screening programmes programmes
Dr. Mark Pearson

Research Fellow, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Queensland 4878, Australia
Interests: Mark’s major research focus involves looking at the functions of proteins from human parasites (specifically helminths, or worms) and how these molecules interact with the host immune system. He is particularly interested in understanding these processes in the context of developing vaccines against parasites of third world populations and finding novel therapies for autoimmune disorders such as asthma
Prof. Dr. John K. Rose

Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
Interests: virology; vaccine and gene expression vectors based on rhabdoviruses; membrane protein assembly, transport and targeting; viral assembly
Prof. Dr. Pramod K. Srivastava

Center for Immunotherapy of Cancer and Infectious Diseases, University of Connecticut School of Medicine, Farmington, CT 06030-1601, USA
Interests: antigen presentation by MHC I and MHC II molecules; immune response to cancer; viral immunity and autoimmunity
Dr. Stanley S. Tai

Department of Microbiology, College of Medicine, Howard University, 520 “W” Street, NW, Washington, DC 20059, USA
Interests: pneumococcal vaccine; respiratory bacterial pathogens; bacterial pathogenesis
Contribution: Special Issue: Pneumococcal Vaccine in the 21st Century
Prof. Dr. Sjoerd H. van der Burg

Department of Oncology, Section Experimental Cancer Immunology and Therapy, K1-P, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
Interests: The aim of my laboratory is to optimally implement immunotherapy as treatment modality for patients with solid tumors. The program is focused on the exploration of key factors in host-tumor interactions that determine successes and failures in immune control of cancer in order to drive the improvement of our immunotherapeutic strategies against solid tumors. Keywords: therapeutic vaccines, immunotherapy, peptides, HPV, chronic viral infections, cancer
Prof. Dr. Zhou Xing

McMaster Immunology Research Centre, Department of Pathology & Molecular Medicine, Rm. MDCL-4012, McMaster University, 1280 Main St. West, Hamilton, Ontario L8S 4K1, Canada
Interests: infectious diseases; pulmonary infectious disease; T cell immunity; vaccines; mucosal vaccination
Dr. Shi-Yu Yang

Division of Surgery & Interventional Science, University College London, Rowland Hill Street, London, NW3 2PF, UK
Interests: colorectal cancer, stem cells; regenerative medicine
Prof. Dr. XiaoJian Yao

Laboratory of Molecular Human Retrovirology, Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, 745 Bannatyne Avenue, Room 508, Basic Medical Science Building, Winnipeg, MB R3E 0J9, Canada
Interests: Virus/host interactions required for HIV replication; Development of Anti-HIV vaccines; Anti-HIV gene therapy
Dr. Martin Villalba Gonzalez

INSERM-UM1 U1040, Université de Montpellier 1, 34295 Montpellier Cedex 5, France
Interests: antitumor immunotherapy; cell therapy; NK cell; monoclonal antibodies; antibody-dependent cell cytotoxicity; MAPK; metabolism; dichloroacetate
Dr. Pedro A. Reche

Facultad de Medicina, Dpto. Microbiology I – Immunology, Universidad Complutense de Madrid, Pza. Ramón y Cajal, Ciudad Universitaria, Madrid 28040, Spain
Interests: Immunoinformatics, protein engineering, antigen presentation and processing, HLA, epitope, prediction, immunotherapy, vaccines
Dr. Florian Krammer

Icahn School of Medicine at Mount Sinai, New York, One Gustave L. Levy Place, 10029 NY, Box 1124, USA
Interests: influenza virus; avian influenza; universal influenza virus vaccines; hemagglutinin; neuraminidase; stalk-reactive antibodies; zoonotic viral infections; emerging viruses; viral glycoproteins
Prof. Dr. Massimo Zollo

Department of Molecular Medicine and Medical Biotechnology, Federico II Faculty of Naples, Italy
Interests: Human Genetics; Functional Genomics and Biotechnology; Molecular Biology and Oncology; Tumor Microenvironment; Metastasis; Paediatric Brain tumours; cell immunology; metastatic niche
Prof. Nirbhay Kumar

Department of Tropical Medicine, School of Public Health & Tropical Medicine, Director, Vector-Borne Infectious Diseases Research Center, Tulane University, 333 S. Liberty Street, Mail Code-8317, New Orleans, LA 70112, USA
Interests: malaria; vaccines; immunology; genomics; helminthes and co-infection; malaria transmission; malaria drugs and diagnostics
Dr. Vjollca H. Konjufca

Department of Microbiology, Southern Illinois University, Carbondale, IL 62901, USA
Interests: mucosal immunology; antibodies; nanoparticles; mucosal vaccines; prime-boost immunization; Salmonella pathogenesis; female reproductive tract; antigen uptake and transport; spleen; goblet cells
Prof. Dr. Walter J. Storkus

Department of Dermatology, Immunology, Bioengineering and Pathology, University of Pittsburgh School of Medicine, W1151 Biomedical Sciences Tower, 200 Lothrop Street Pittsburgh, PA 15213, USA
Interests: Cancer vaccine; Immunotherapy; Cytotoxic T Cells; Dendritic Cells; pitope Spreading; giogenesis; Vascular Normalization
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert